These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 16632079)

  • 41. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
    Villegas A; Arrizabalaga B; Fernández-Lago C; Castro M; Mayans JR; González-Porras JR; Duarte RF; Remacha AF; Luño E; Gasquet JA
    Curr Med Res Opin; 2011 May; 27(5):951-60. PubMed ID: 21381892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
    Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
    Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study.
    Tsuboi M; Ezaki K; Tobinai K; Ohashi Y; Saijo N
    Jpn J Clin Oncol; 2009 Mar; 39(3):163-8. PubMed ID: 19164318
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
    Chang J; Couture F; Young S; McWatters KL; Lau CY
    J Clin Oncol; 2005 Apr; 23(12):2597-605. PubMed ID: 15452188
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia.
    Bustos A; Álvarez R; Aramburo PM; Carabantes F; Díaz N; Florián J; Lázaro M; de Segovia JM; Gasquet JA; Alegre A;
    Curr Med Res Opin; 2012 Jan; 28(1):57-67. PubMed ID: 22070513
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm.
    Skali H; Lin J; Pfeffer MA; Chen CY; Cooper ME; McMurray JJ; Nissenson AR; Remuzzi G; Rossert J; Parfrey PS; Scott-Douglas NW; Singh AK; Toto R; Uno H; Ivanovich P
    Am J Kidney Dis; 2013 Feb; 61(2):238-46. PubMed ID: 23159232
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
    Witzig TE; Silberstein PT; Loprinzi CL; Sloan JA; Novotny PJ; Mailliard JA; Rowland KM; Alberts SR; Krook JE; Levitt R; Morton RF
    J Clin Oncol; 2005 Apr; 23(12):2606-17. PubMed ID: 15452187
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration.
    Toto RD; Pichette V; Navarro J; Brenner R; Carroll W; Liu W; Roger S
    Am J Nephrol; 2004; 24(4):453-60. PubMed ID: 15331889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure.
    Kourea K; Parissis JT; Farmakis D; Paraskevaidis I; Panou F; Filippatos G; Kremastinos DT
    Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):365-9. PubMed ID: 18525396
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide.
    Pirker R; Ramlau RA; Schuette W; Zatloukal P; Ferreira I; Lillie T; Vansteenkiste JF
    J Clin Oncol; 2008 May; 26(14):2342-9. PubMed ID: 18467726
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial.
    Lewis EF; Pfeffer MA; Feng A; Uno H; McMurray JJ; Toto R; Gandra SR; Solomon SD; Moustafa M; Macdougall IC; Locatelli F; Parfrey PS;
    Clin J Am Soc Nephrol; 2011 Apr; 6(4):845-55. PubMed ID: 21212421
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The relationship between patient knowledge of hemoglobin levels and health-related quality of life.
    Kallich J; McDermott A; Xu X; Fayers P; Cella D
    Qual Life Res; 2006 Feb; 15(1):57-68. PubMed ID: 16411031
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy.
    Berndt E; Kallich J; McDermott A; Xu X; Lee H; Glaspy J
    Pharmacoeconomics; 2005; 23(5):505-14. PubMed ID: 15896101
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy.
    Cella D; Viswanathan HN; Hays RD; Mendoza TR; Stein KD; Pasta DJ; Foreman AJ; Vadhan-Raj S; Kallich JD
    Cancer; 2008 Sep; 113(6):1480-8. PubMed ID: 18642348
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quality of life and clinical decisions in chemotherapy-induced anemia.
    Cella D
    Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):25-8. PubMed ID: 16925108
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interim data suggest major response with darbepoetin in anemic MDS patients.
    Oncology (Williston Park); 2005 Aug; 19(9):1139. PubMed ID: 16255131
    [No Abstract]   [Full Text] [Related]  

  • 59. The effects of anemia and anemia treatment on the quality of life of people with cancer.
    Cella D
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):125-32. PubMed ID: 12380962
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient-reported outcomes after acute nonvariceal upper gastrointestinal hemorrhage.
    Bager P; Dahlerup JF
    Scand J Gastroenterol; 2014 Aug; 49(8):909-16. PubMed ID: 24945872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.